Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 54 New Drugs Approved in 1st Half of FY2007: PMDA
January 7, 2008
- AstraZeneca to Start PI for 20 Products in 2008, as in 2007: CEO D. Brennan
January 7, 2008
- 7 New Products Included in NHI Price List
January 7, 2008
- Eisai Goes on the Offensive in Oncology by Acquiring MGI Pharma
December 24, 2007
- Plavix Contributes to Strong Growth in Sales of Antithrombotics: IMS
December 24, 2007
- Record-High Monthly Sales with 500 Fewer MRs: Pfizer Japan
December 24, 2007
- Novo Nordisk Aims at Top Share with Levemir
December 24, 2007
- Geninax Captures 1st Place in October
December 24, 2007
- BUSINESS NEWS IN BRIEF
December 24, 2007
- Re-Pricing, Special Price Cut to Be Less Harsh Than in FY2006: FY2008 Price Revision
December 24, 2007
- Bargaining over Revision Rates Enters Final Stage
December 24, 2007
- 16 Products (9 APIs) Receive NHI Price Listing
December 24, 2007
- 79 Deaths Reported in Patients Taking Enbrel: Wyeth
December 24, 2007
- REGULATORY NEWS IN BRIEF
December 24, 2007
- TOPICS／Takeda Regarded as Most Enthusiastic about R&D by Pharmacists: Nextit survey
December 24, 2007
- R&D NEWS IN BRIEF
December 24, 2007
- Astellas R&D Meeting: Promising PIIb Results Presented on Oral Factor Xa Inhibitor
December 24, 2007
- OPINION／The Power of Positive People Makes My Day
December 24, 2007
- Development Status of New Drugs for IBD Updated: JHSF Seminar
December 24, 2007
- MEDICAL DEVICE NEWS IN BRIEF
December 24, 2007
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…